Hussman Strategic Advisors’s Harvard Bioscience HBIO Stock Holding History

Hussman Strategic Advisors’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-90,800	Closed	-$5.15M	–	199
2014 Q4	$5.15M	Sell	90,800 -2,200	-2%	-$105K	0.51%	81
2014 Q3	$3.8M	Hold	93,000	–	–	0.33%	112
2014 Q2	$4.23M	Hold	93,000	–	–	0.33%	105
2014 Q1	$4.41M	Hold	93,000	–	–	0.33%	100
2013 Q4	$4.37M	Sell	93,000 -38,900	-29%	-$1.7M	0.31%	103
2013 Q3	$5.26M	Hold	131,900	–	–	0.29%	101
2013 Q2	$4.73M	Buy	+131,900	New	+$5.05M	0.22%	122

Other funds holding HBIO

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Hussman Strategic Advisors's HBIO Position: Q1 2015 in Review

Hussman Strategic Advisors sold out of Harvard Bioscience (HBIO) in Q1 2015, closing a stake of 90,800 shares — an estimated $5.15M sold.

Hussman Strategic Advisors first reported a position in HBIO in Q2 2013 and held it in 7 quarters. The position peaked at $5.26M in Q3 2013. 79 funds tracked by Wall St. Rank hold HBIO as of Q1 2015.

Hussman Strategic Advisors reported no remaining Harvard Bioscience position as of Q1 2015 after selling out during the quarter.
Hussman Strategic Advisors sold 90,800 Harvard Bioscience shares in Q1 2015, an estimated $5.15M.
Hussman Strategic Advisors first reported a position in Harvard Bioscience in Q2 2013 and held it in 7 quarters.
Hussman Strategic Advisors's Harvard Bioscience position peaked at $5.26M in Q3 2013.
79 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2015.

Based on Hussman Strategic Advisors's 13F filing for Q1 2015, filed 1 May 2015.